Agomab Therapeutics is set to acquire Origo Biopharma, enhancing its therapeutic pipeline focused on targeting fibrosis-related disorders through innovative small molecule development.

Target Company Overview

Agomab Therapeutics NV has announced a definitive agreement to acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology firm. Origo specializes in developing organ-restricted small molecule drug candidates that target the transforming growth factor beta (TGF-β) pathway, aimed at treating fibrosis-related disorders. This acquisition aligns with Agomab's mission to innovate therapies based on growth factor signaling pathways, further enhancing its commitment to addressing fibrosis and organ failure through a diversified clinical pipeline.

Origo Biopharma, based in Galicia and Barcelona, is renowned for its development of novel organ-restricted small molecule entities, ensuring localized TGF-β inhibition while mitigating systemic toxicity risks. The company's leading drug candidate, ORG-129, is currently undergoing a Phase 1 clinical trial, targeting fibrostenotic Crohn's disease, while its second candidate, ORG-447, aims at idiopathic pulmonary fibrosis and is in the IND-enabling studies phase.

Industry Overview in Spain

The biotechnology industry in Spain has exhibited significant growth, driven by advancements in research and development, and a robust academic ecosystem fostering inno